EDIT Earnings: *Mon 9-NOV-2026
|
End of day quotes updated Fri Sep 18 15:45 CST
🏠
🔍
|
| 18-Sep-2026 |
2.70 |
-0.02 {-0.7 %} |
V: 15,011,397 |
|
| EDIT |
18-Sep-2026 |
Close: 2.70 |
-0.02 {-0.7 %} |
Volume: 15,011,397 |
|
|
|
|
|
|
|
|
27-Jul-2026
29-May-2026
28-Nov-2025
|
|
|
|
|
|
EDIT
|
SPY
|
|
-0.7
0.0
-11.8
-16.7
31.7
|
-0.1
-0.3
-0.7
2.0
11.7
|
|
% Price Gain
WTD Performance (%)
MTD Performance (%)
QTD Performance (%)
YTD Performance (%)
|
SPY tracks S&P 500 index.
|
|
15 minute intraday candlestick chart, ~15 minute delay
15 minute intraday candlestick chart, ~15 minute delay
|
| EDIT News | 11-Sep-2026 - Yahoo Finance
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose ... | 8-Sep-2026 - Yahoo Finance
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial ... | 7-Sep-2026 - Yahoo Finance
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Dan Ory, M.D. Editas Medicine today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today. | 7-Aug-2026 - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)
Detailed price information for Editas Medicine (EDIT-Q) from The Globe and Mail including charting and trades. | 6-Aug-2026 - Zacks Investment Research
EDIT Q2 earnings beat estimates, revenues rise, pipeline in focus
Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus ... | 5-Aug-2026 - Zacks
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of ... | 5-Aug-2026 - Markets Insider
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT-401 on track for CTN submission this month with data update in Q1 2027Recently presented pre-clinical data demonstrating ~90% or greater ... | 31-May-2026 - Yahoo Finance
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ... | 26-May-2026 - Yahoo Finance
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious ... | | | |
Disclaimer
Privacy
Contact
Copyright © 2001-2026, All rights reserved.
HotCandlestick.com, LLC
|
